ES2266245T3 - Gen de la calicreina. - Google Patents

Gen de la calicreina. Download PDF

Info

Publication number
ES2266245T3
ES2266245T3 ES01966837T ES01966837T ES2266245T3 ES 2266245 T3 ES2266245 T3 ES 2266245T3 ES 01966837 T ES01966837 T ES 01966837T ES 01966837 T ES01966837 T ES 01966837T ES 2266245 T3 ES2266245 T3 ES 2266245T3
Authority
ES
Spain
Prior art keywords
protein
baselineskip
klk15
nucleic acid
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01966837T
Other languages
English (en)
Spanish (es)
Inventor
George M. Yousef
Eleftherios P. Diamandis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mt Sinai Hospital
Original Assignee
Mt Sinai Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mt Sinai Hospital filed Critical Mt Sinai Hospital
Application granted granted Critical
Publication of ES2266245T3 publication Critical patent/ES2266245T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21034—Plasma kallikrein (3.4.21.34)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES01966837T 2000-08-11 2001-08-10 Gen de la calicreina. Expired - Lifetime ES2266245T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22485300P 2000-08-11 2000-08-11
US224853P 2000-08-11

Publications (1)

Publication Number Publication Date
ES2266245T3 true ES2266245T3 (es) 2007-03-01

Family

ID=22842508

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01966837T Expired - Lifetime ES2266245T3 (es) 2000-08-11 2001-08-10 Gen de la calicreina.

Country Status (9)

Country Link
US (2) US7199229B2 (https=)
EP (1) EP1309703B1 (https=)
JP (1) JP2004505649A (https=)
AT (1) ATE330017T1 (https=)
AU (2) AU8738401A (https=)
CA (1) CA2418422C (https=)
DE (1) DE60120712T2 (https=)
ES (1) ES2266245T3 (https=)
WO (1) WO2002014485A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022497B1 (en) * 1999-03-11 2006-04-04 Mt. Sinai Hospital Human kallikrein-like genes
US9012141B2 (en) * 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
WO2002014485A2 (en) 2000-08-11 2002-02-21 Mount Sinai Hospital Kallikrein gene
ATE365922T1 (de) * 2000-10-27 2007-07-15 Mount Sinai Hospital Corp Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
JP2004512540A (ja) 2000-11-01 2004-04-22 マウント・サイナイ・ホスピタル 卵巣癌の検出
US20040203012A1 (en) * 2001-05-25 2004-10-14 Eleftherios Diamandis Method of detecting and monitoring prostate and ovarian cancers
CA2463920A1 (en) * 2001-10-16 2003-04-24 Mount Sinai Hospital Methods for detecting ovarian cancer
AU2003269618A1 (en) * 2002-08-28 2004-03-19 Mount Sinai Hospital Methods for detecting breast and ovarian cancer
CA2497061A1 (en) * 2002-08-28 2004-03-11 Mount Sinai Hospital Methods for detecting endocrine cancer using kallikrein 13 (klk13) as a biomarker
EP1546728A2 (en) * 2002-09-26 2005-06-29 Mount Sinai Hospital Methods for detecting endocrine cancer
CA2516591A1 (en) * 2003-02-26 2004-09-10 Mount Sinai Hospital Multiple marker assay for detection of ovarian cancer
WO2004077060A2 (en) * 2003-02-27 2004-09-10 Mount Sinai Hospital Assay for detection of renal cell carcinoma
CA2468651A1 (en) * 2003-06-13 2004-12-13 Eleftherios P. Diamandis Detection of neurodegenerative diseases
US20060269971A1 (en) * 2003-09-26 2006-11-30 Mount Sinai Hospital Methods for detecting prostate cancer
EP1711616A1 (en) * 2004-01-28 2006-10-18 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with kallikrein 15 (klk15)
US20110129499A1 (en) 2008-05-19 2011-06-02 Paulo Maciag Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
US9226958B2 (en) 2010-10-01 2016-01-05 University Of Georgia Research Foundation, Inc. Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
AU2012229218B2 (en) 2011-03-11 2017-03-02 Advaxis, Inc. Listeria-based adjuvants
CN104411327A (zh) 2012-03-12 2015-03-11 阿德瓦希斯公司 李斯特菌疫苗治疗以后的抑制细胞功能抑制
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022497B1 (en) 1999-03-11 2006-04-04 Mt. Sinai Hospital Human kallikrein-like genes
US20020064856A1 (en) * 2000-06-26 2002-05-30 Gregory Plowman Novel proteases
JP2004515220A (ja) * 2000-07-21 2004-05-27 インサイト・ゲノミックス・インコーポレイテッド プロテアーゼ
WO2002014485A2 (en) 2000-08-11 2002-02-21 Mount Sinai Hospital Kallikrein gene
CA2360219A1 (en) 2000-10-27 2002-04-27 Mount Sinai Hospital Method for detecting alzheimer's disease
ATE365922T1 (de) * 2000-10-27 2007-07-15 Mount Sinai Hospital Corp Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
JP2004512540A (ja) * 2000-11-01 2004-04-22 マウント・サイナイ・ホスピタル 卵巣癌の検出
US20040203012A1 (en) * 2001-05-25 2004-10-14 Eleftherios Diamandis Method of detecting and monitoring prostate and ovarian cancers
CA2463920A1 (en) * 2001-10-16 2003-04-24 Mount Sinai Hospital Methods for detecting ovarian cancer
US20050287528A1 (en) 2002-04-04 2005-12-29 Mount Sinai Hospital Methods for detecting ovarian cancer
CA2497061A1 (en) 2002-08-28 2004-03-11 Mount Sinai Hospital Methods for detecting endocrine cancer using kallikrein 13 (klk13) as a biomarker
AU2003269618A1 (en) 2002-08-28 2004-03-19 Mount Sinai Hospital Methods for detecting breast and ovarian cancer
EP1546728A2 (en) 2002-09-26 2005-06-29 Mount Sinai Hospital Methods for detecting endocrine cancer
CA2516591A1 (en) 2003-02-26 2004-09-10 Mount Sinai Hospital Multiple marker assay for detection of ovarian cancer
WO2004077060A2 (en) 2003-02-27 2004-09-10 Mount Sinai Hospital Assay for detection of renal cell carcinoma
CA2468651A1 (en) 2003-06-13 2004-12-13 Eleftherios P. Diamandis Detection of neurodegenerative diseases
US20060269971A1 (en) 2003-09-26 2006-11-30 Mount Sinai Hospital Methods for detecting prostate cancer

Also Published As

Publication number Publication date
CA2418422A1 (en) 2002-02-21
AU2001287384B2 (en) 2007-03-29
JP2004505649A (ja) 2004-02-26
WO2002014485A2 (en) 2002-02-21
US7507403B2 (en) 2009-03-24
EP1309703A2 (en) 2003-05-14
US20040058342A1 (en) 2004-03-25
AU8738401A (en) 2002-02-25
ATE330017T1 (de) 2006-07-15
DE60120712D1 (en) 2006-07-27
CA2418422C (en) 2011-06-07
DE60120712T2 (de) 2007-07-19
WO2002014485A3 (en) 2003-01-09
US20070178114A1 (en) 2007-08-02
US7199229B2 (en) 2007-04-03
EP1309703B1 (en) 2006-06-14

Similar Documents

Publication Publication Date Title
ES2266245T3 (es) Gen de la calicreina.
ES2849426T3 (es) Antídotos para inhibidores del factor Xa y procedimientos de uso de los mismos
AU2001287384A1 (en) Kallikrein gene
ES2607935T3 (es) Antídotos para inhibidores del factor Xa y procedimientos de uso de los mismos
US8735066B2 (en) Tumor suppressor designated TS10Q23.3
ES2605801T3 (es) Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
KR20040022208A (ko) 변형 단백질, 디자이너 독소, 및 이들의 제조 방법
ES2305093T3 (es) Regulacion de la serina proteasa transmembrana humana.
JP4454670B2 (ja) Ｔｓ１０ｑ２３．３と称する腫瘍抑制因子
EP1159431A2 (en) Human kallikrein-like genes
ES2361044T3 (es) Un supresor de tumor designado ts10q23.3.
US7022497B1 (en) Human kallikrein-like genes
JP2009148264A (ja) 膀胱癌、卵巣癌、肺癌、および腎臓癌の診断および治療に有用な腫瘍抗原
ES2256957T3 (es) Serina-proteasa extracelular.
JP2000504218A (ja) リガンド指令酵素プロドラッグ療法
JP2003528584A (ja) Ｐｒｏｓｔ０７ポリペプチドをコードするｄｎａ
WO2002063013A2 (en) Human acid phosphatase gene
US20020110862A1 (en) Novel Siglec-like gene
EP1724351A2 (en) Human Kallikrein-like genes
US20120213789A1 (en) New Molecular Target for Treatment of Cancer
CA2357074A1 (en) Novel bcl-2 related proline rich protein (bpr)